The c-myc oncogene: Use of a biological prognostic marker as a potential target for gene therapy in melanoma

British Journal of Plastic Surgery

Volumn 55, Issue 8, 2002, Pages 623-627

  Chana, Jagdeep S ^a   Grover, Rajiv ^a   Tulley, Paul ^a   Lohrer, Horst ^a   Sanders, Roy ^a   Grobbelaar, Adriaan O ^a   Wilson, George D ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

c myc; Gene therapy; Melanoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; MYC PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; TREATMENT OUTCOME;

EID: 0036459914     PISSN: 00071226     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjps.2002.3964     Document Type: Article

References (29)

1. Littlewood TD, Evan GI. The role of myc oncogenes in cell growth and differentiation [published erratum appears in Adv Dent Res 1991; 5: 87]. Adv Dent Res 1990; 4: 69-79.
2. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genet Dev 1993; 3: 44-9.
3. Lu X, Park SH, Thompson TC, Lane DP. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 1992; 70: 153-61.
4. Kraehn GM, Utikal J, Udart M, et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 2001; 84: 72-9.
5. Greulich KM, Utikal J, Peter RU, Krahn G. c-MYC and nodular malignant melanoma. A case report. Cancer 2000; 89: 97-103.
6. Shlagbauer-Wadl H, Griffioen M, van Elsas A, et al. C-myc gene expression positively correlates with metastatic potential of human melanoma in SCID mice. Melanoma Res 1997; 7(S1): 6.
7. Grover R, Ross DA, Richman PI, et al. C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity. Eur J Surg Oncol 1996; 22: 342-6.
8. Grover R, Ross DA, Wilson GD, Sanders R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br J Plast Surg 1997; 50: 478-82.
9. Grover R, Grobbelaar AO, Hudson DA, et al. The clinical significance of oncogene expression in subungual melanoma. Br J Plast Surg 1997; 50: 15-19.
10. Grover R, Chana J, Grobbelaar AO, et al. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Br J Plast Surg 1999; 52: 122-6.
11. Chana JS, Grover R, Wilson GD, et al. The clinical significance of c-myc oncogene expression in melanomas of the scalp. Br J Plast Surg 1998; 51: 191-4.
12. Kregnow D, Ratajczak MZ, Gewirtz AM. Disrupting the flow of genetic information with antisense oligodeoxynucleotides: research and therapeutic applications. In Akhtar S, ed. Delivery Strategies for Antisense Oligonucleotide Therapeutics. New York: CRC Press, 1995: 1-15.
13. Heikkila R, Schwab G, Wickstrom E, et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987; 328: 445-9.
14. Degols G, Leonetti JP, Mechti N, Lebleu B. Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene. Nucleic Acids Res 1991; 19: 945-8.
15. Plenat F. Animal models of antisense oligonucleotides: lessons for use in humans. Mol Med 1996; 2: 225-67.
16. Broaddus WC, Chen ZC, Prabhu SS, et al. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery 1997; 41: 908-15.
17. Cerutti J, Trapasso F, Battaglia C, et al. Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human carcinoma thyroid cell lines. Clin Cancer Res 1996; 2: 119-26.
18. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994; 74: 2546-54.
19. Kimura S, Maekawa T, Hirakawa K, et al. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995; 55: 1379-84.
20. Robinson LA, Smith LJ, Fontaine MP, et al. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg 1995; 60: 1583-91.
21. Saijo Y, Uchiyama B, Abe T, et al. Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition. Jpn J Cancer Res 1997; 88: 26-33.
22. Burgess TL, Fisher EF, Ross SL, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995; 92: 4051-5.
23. Leonetti C, D'Agnano I, Lozupone F, et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996; 88: 419-29.
24. Ginobbi P, Geiser TA, Ombres D, Citro G. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res 1997; 17: 29-35.
25. Williams SA, Chang L, Buzby JS, et al. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth. Leukemia 1996; 10: 1980-9.
26. Versteeg R, Noordermeer IA, Kruse Wolters M, et al. c-myc down-regulates class I HLA expression in human melanomas. EMBO J 1988; 7: 1023-9.
27. Versteeg R, Kruse Wolters KM, Plomp AC, et al. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med 1989; 170: 621-35.
28. Inghirami G, Grignani F, Sternas L, et al. Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. Science 1990; 250: 682-6.
29. Peltenburg LT, Schrier PI. Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements. Immunogenetics 1994; 40: 54-61.